Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients.

J Immunol Res · 2015 · PMC4518147 · PMID 26258149

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Other clinical trials in the context of graft-versus-host disease (GVHD) or hematopoietic stem cell transplantation (HSCT) also showed a trend to more infections after MSC therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.